WallStreetZenWallStreetZen

NASDAQ: ACAD
Acadia Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Acadia Pharmaceuticals revenue was $957.80M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $259.6M, up 3.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ACAD annual revenue was $957.8M, with 31.8% growth year-over-year.

ACAD past revenue growth

How has ACAD's revenue growth performed historically?

Company
31.85%
Industry
122.68%
Market
14.46%
ACAD's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ACAD's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ACAD's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ACAD revenue history

Current Revenue
$957.8M
Current Earnings
$226.5M
Current Profit Margin
23.6%

Be the first to know when ACAD announces revenue.

ACAD Revenue History By Year

ACAD Yearly RevenueACAD RevenueACAD ChangeACAD Revenue Growth
2024-12-31$957.80M$231.36M+31.85%
2023-12-31$726.44M$209.20M+40.45%
2022-12-31$517.24M$33.09M+6.83%
2021-12-31$484.15M$42.39M+9.60%
2020-12-31$441.76M$102.68M+30.28%
2019-12-31$339.08M$115.27M+51.50%
2018-12-31$223.81M$98.91M+79.19%
2017-12-31$124.90M$107.57M+620.68%
2016-12-31$17.33M$17.27M+28,311.48%
2015-12-31$61.00k-$59.00k-49.17%
2014-12-31$120.00k-$1.03M-89.52%
2013-12-31$1.15M-$3.76M-76.67%
2012-12-31$4.91M$2.84M+137.40%
2011-12-31$2.07M-$40.07M-95.09%
2010-12-31$42.14M$35.74M+558.46%
2009-12-31$6.40M$4.81M+302.45%
2008-12-31$1.59M-$5.97M-78.95%
2007-12-31$7.56M-$578.00k-7.11%
2006-12-31$8.13M-$2.82M-25.77%
2005-12-31$10.96M$6.35M+137.97%
2004-12-31$4.60M-$2.77M-37.60%
2003-12-31$7.38M$1.10M+17.57%
2002-12-31$6.28M$2.56M+68.98%
2001-12-31$3.71MN/AN/A

1 of 2

Acadia Pharmaceuticals Revenue FAQ

What was ACAD's revenue last quarter?

On Invalid Date, Acadia Pharmaceuticals (NASDAQ: ACAD) reported Q4 2024 revenue of $259.60 million up 12.36% year over year. In the same quarter last year, Acadia Pharmaceuticals's revenue was $231.04 million.

What was Acadia Pharmaceuticals's revenue in 2024?

Acadia Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $957.80 million, a 31.85% increase year over year.

How much does Acadia Pharmaceuticals make in a day?

Based on Acadia Pharmaceuticals annual revenue for the past five years, ACAD makes an average of $1,713,626.85 per day.

What was Acadia Pharmaceuticals's annual revenue growth in the past year?

As of Q1 2025, Acadia Pharmaceuticals's revenue has grown 31.85% year over year. This is 90.83 percentage points lower than the US Biotechnology industry revenue growth rate of 122.68%. Acadia Pharmaceuticals's revenue in the past year totaled $957.80 million.

How much does Acadia Pharmaceuticals make in a year?

Acadia Pharmaceuticals's revenue by year for the past five years is:
  • Acadia Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $957.80 million, a 31.85% increase year over year.
  • Acadia Pharmaceuticals's annual revenue for Dec 31, 2023 was $726.44 million, a 40.45% increase from 2022.
  • Acadia Pharmaceuticals's annual revenue for 2022 was $517.24 million, a 6.83% increase from 2021.
  • Acadia Pharmaceuticals's annual revenue for 2021 was $484.15 million, a 9.6% increase from 2020.
  • Acadia Pharmaceuticals's annual revenue for 2020 was $441.76 million, a 30.28% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.